Company Overview

Illumina, Inc. is a global leader in providing sequencing- and array-based solutions for genetic and genomic analysis. The company operates across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. Its offerings include sequencing- and array-based instruments and consumables, such as reagents, flow cells, and library preparation kits. Illumina also provides specialized kits for whole-genome sequencing (WGS), targeted resequencing, genotyping, noninvasive prenatal testing (NIPT), and associated product support services. The company's revolutionary technology has been instrumental in generating over 90% of the world's sequencing data. Incorporated in 1998, Illumina, Inc. is headquartered in San Diego, California.

Market Position and Industry Leadership

Illumina stands at the forefront of the genomics industry, providing essential tools and services for analyzing genetic material, with broad applications in life science research and clinical laboratories. The company is recognized as a global leader in DNA sequencing and array-based technologies, driving significant breakthroughs in genomics research and enabling critical clinical applications. Its customer base includes genomic research centers, academic institutions, government laboratories, and hospitals, alongside pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics firms. Illumina markets and distributes its products both directly and through life-science distributors.

Financial Performance and Market Position

Illumina's financial performance reflects its market leadership, though it navigates dynamic market conditions. As of September 10, 2025, the company's market capitalization stood at $15.1 billion. The ticker symbol for Illumina is ILMN.

Recent Financial Results (Q2 2025):

- Revenue: $1.06 billion, a 3% decrease from Q2 2024 (reported and constant currency).

- Operating Margin: 20.2% GAAP and 23.8% non-GAAP.

- Earnings Per Share (EPS): $1.49 GAAP diluted EPS and $1.19 non-GAAP diluted EPS.

- Free Cash Flow: $204 million for the quarter.

- Trailing 12-Month Revenue (as of March 31, 2025): $4.34 billion.

2025 Fiscal Year Guidance:

- Total Reported Revenue: Expected to be between $4.23 billion and $4.31 billion (representing a constant currency decline of 0.5%-2.5%).

- Non-GAAP EPS: Guidance raised by $0.25 at the midpoint to $4.45-$4.55.

- Non-GAAP Operating Margin: Guidance raised by 50 basis points to 22%-22.5%.

Key Financial Metrics

- Market Capitalization: $15.1 Billion (as of September 10, 2025)

- Stock Symbol: ILMN

- Q2 2025 Revenue: $1.06 Billion

- Trailing 12-Month Revenue: $4.34 Billion (as of March 31, 2025)

- FY 2025 Revenue Guidance: $4.23 - $4.31 Billion

- FY 2025 Non-GAAP EPS Guidance: $4.45 - $4.55

Business Operations and Production Capacity

Illumina maintains a significant global operational footprint, with 8,970 total employees worldwide. Its operations encompass 17 commercial sites and two manufacturing, research, and development facilities. The company's production capacity supports its extensive product portfolio, which is critical for meeting global demand in genomics and genetic analysis.

Product Portfolio and Innovation

Illumina offers a comprehensive suite of products, including kits and reagents, instruments, selection tools, and software for analysis. Key offerings feature solutions like the Illumina COVIDSeq test, AmpliSeq for Illumina, the TruSight Oncology 500 product family, Illumina DNA prep, the NextSeq 2000 Sequencing System, and Illumina RNA Prep with Enrichment. The company consistently invests in innovation, evidenced by recent product developments such as TruSight Oncology 500 version 2 (TSO 500 v2), an advanced genomic profiling assay for cancer research, and positive market adoption of the MiSeq I 100 Plus system.

Strategic Initiatives and Market Expansion

Illumina is actively pursuing strategic growth initiatives, notably its multiomics strategy. This includes the proposed $350 million cash acquisition of Somalogic from Standard Biotools, complemented by potential performance-based milestones and royalties, aimed at significantly expanding Illumina's affinity-based proteomics portfolio. The company is also focused on expanding its presence in the clinical market, with sequencing throughput on its high and mid-throughput instruments growing at over 30% year-over-year, driven by strong demand in clinical applications.

Company Operations and Workforce

Illumina employs a dedicated workforce of over 7,300 employees across its global operations, contributing to its robust R&D and commercial activities. The company has also garnered recognition for its corporate practices, being named to TIME's World's Most Sustainable Companies list for two consecutive years and U.S. News & World Report's Best Companies to Work For list.

Market Challenges and Outlook

Illumina is navigating a challenging market environment, particularly within the research segment, where budget constraints among academic and government customers in the US present headwinds. However, its business in Greater China remains resilient and supportive of its differentiated technology. Executives express confidence in achieving targeted high single-digit revenue growth and non-GAAP margin expansion by 2027, underpinned by a shift towards a more favorable clinical segment mix and leveraging operational efficiencies. The company's leading position in genomics innovation, strong clinical market penetration, and strategic investments in multiomics capabilities position it for sustained long-term growth in the expanding global genomics market.